Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2019.159 | A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.457 | A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.022 | Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients? |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.658 | A Phase 1b/2 Open-label Study of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either 5-Fluorouracil or Capecitabine Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction |
Dr. LOONG Herbert Ho Fung 龍浩鋒 醫生 |
| 2018.553 | A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.541 | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.453 | An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.040 | A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.366 | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.296 | A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer | Dr. LOONG Herbert Ho Fung |
| 2019.554 | A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 105) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.376 | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2020.020 | A single-arm, open-label, phase 2 study of dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.652 | A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors | Dr. LOONG Herbert Ho Fung |
| 2020.198 | Clinical Application of a Personalized Circulating Tumour DNA (ctDNA) Assay for Early Detection of Cancer Relapse |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.523 | Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.179 | A Phase 2 Study of Oraxol in Subjects with Cutaneous Angiosarcoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.375 | Prospective Molecular Profiling in Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.386 | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms | Dr. LOONG Herbert Ho Fung |
| 2026.444 | A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors | Dr. LOONG Herbert Ho Fung |
| 2026.387 | Death anxiety among advanced lung cancer patients and their family members: A mixed method study | Dr. LOONG Herbert Ho Fung |
| 2026.508 | Effectiveness of a multi-component self-management intervention for anxiety and respiratory-related symptoms in patients with lung cancer: a 3-arm randomized controlled trial | Dr. LOONG Herbert Ho Fung |
| 2026.586 | A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia | Dr. LOONG Herbert Ho Fung |
| 2026.389 | A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion (MountainTap-5) | Dr. LOONG Herbert Ho Fung |
| 2025.182 | Effectiveness of Instant Messages-delivered Physical Activity e-Coaching and Training (IMPACT) Intervention on Cancer-Related Cognitive Impairment in Lung Cancer Survivors: A Randomized Controlled Trial | Dr. LOONG Herbert Ho Fung |
| 2026.065 | The development and evaluation of a co-designed, AI-based information-providing chatbot for sarcoma patients: A pilot randomised controlled trial | Prof. Loong Herbert Ho Fung |
| 2024.592 | A Phase 2 Study Evaluating the Efficacy, Safety,Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) | Dr. LOONG Herbert Ho Fung |
| 2024.441 | A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1 | Dr. LOONG Herbert Ho Fung |
| 2024.576 | A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) | Dr. LOONG Herbert Ho Fung |
| 2024.347 | Cross-cultural adaptation and validation of the Oxford dyspnoea word cue set for stimulation of emotional processing in lung cancer patients | Dr. LOONG Herbert Ho Fung |
| 2025.608 | Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations | Dr. LOONG Herbert Ho Fung |
| 2024.269 | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations. | Dr. LOONG Herbert Ho Fung |
| 2025.235 | A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR) | Dr. LOONG Herbert Ho Fung |
| 2025.359 | A two-part phase 1 open-label safety and pharmacokinetic study of intravenous RC220 in combination with doxorubicin in adult patients with solid tumours | Dr. LOONG Herbert Ho Fung |
| 2025.628 | A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants with Advanced Solid Tumors | Dr. LOONG Herbert Ho Fung |
| 2026.007 | DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer | Dr. LOONG Herbert Ho Fung |
| 2024.425 | An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors | Dr. LOONG Herbert Ho Fung |
| 2025.317 | Effectiveness of a Mindfulness-Oriented Respiratory Distress Symptom Intervention for Patients with Lung Cancer and Its Association with Brain Activity Changes | Dr. LOONG Herbert Ho Fung |
| 2024.248 | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | Dr. LOONG Herbert Ho Fung |
| 2025.308 | A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) | Dr. LOONG Herbert Ho Fung |
| 2025.540 | AN OPEN-LABEL, MULTICENTER PHASE I STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2025.365 | A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06) | Dr. LOONG Herbert Ho Fung |
| 2024.319 | An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Dr. LOONG Herbert Ho Fung |
| 2024.397 | Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | Dr. LOONG Herbert Ho Fung |
| 2025.096 | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | Dr. LOONG Herbert Ho Fung |
| 2021.540 | TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.513 | A Pilot Study to Establish a Local Next-Generation Sequencing (NGS) Platform Enhanced with Artificial Intelligence (AI) For high Throughput Molecular Profiling in Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2020.565 | A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2022.341 | A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2022.651 | A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
Page 170 of 288.